CAS
CPRX

CTC Alternative Strategies’s Catalyst Pharmaceutical CPRX Stock Holding History

CTC Alternative Strategies’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-18,000
Closed -$77.9K – 43
2015
Q1 		$77.9K Buy
+18,000
New +$64.9K 0.21% 46

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

CTC Alternative Strategies's CPRX Position: Q2 2015 in Review

CTC Alternative Strategies sold out of Catalyst Pharmaceutical (CPRX) in Q2 2015, closing a stake of 18,000 shares — an estimated $77.9K sold.

CTC Alternative Strategies first reported a position in CPRX in Q1 2015 and held it in 1 quarter. The position peaked at $77.9K in Q1 2015. 87 funds tracked by Wall St. Rank hold CPRX as of Q2 2015.

  • CTC Alternative Strategies reported no remaining Catalyst Pharmaceutical position as of Q2 2015 after selling out during the quarter.
  • CTC Alternative Strategies sold 18,000 Catalyst Pharmaceutical shares in Q2 2015, an estimated $77.9K.
  • CTC Alternative Strategies first reported a position in Catalyst Pharmaceutical in Q1 2015 and held it in 1 quarter.
  • CTC Alternative Strategies's Catalyst Pharmaceutical position peaked at $77.9K in Q1 2015.
  • 87 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2015.

Based on CTC Alternative Strategies's 13F filing for Q2 2015, filed 13 Aug 2015.